Patents Assigned to Genelabs Technologies, Inc.
-
Patent number: 6906103Abstract: The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.Type: GrantFiled: October 23, 2002Date of Patent: June 14, 2005Assignee: Genelabs Technologies, Inc.Inventors: Wentao Zhang, Sebastian Johannes Reinhard Liehr, Mark Douglas Velligan, Natalia B. Dyatkina, Janos Botyanszki, Dong-Fang Shi, Christopher Don Roberts, Alexander Khorlin, Peter Harold Nelson, Joseph Martin Muchowski
-
Publication number: 20050113301Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).Type: ApplicationFiled: December 28, 2004Publication date: May 26, 2005Applicant: Genelabs Technologies, Inc.Inventor: Kenneth Schwartz
-
Patent number: 6869765Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: November 13, 2001Date of Patent: March 22, 2005Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 6854468Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).Type: GrantFiled: February 13, 2003Date of Patent: February 15, 2005Assignee: Genelabs Technologies, Inc.Inventor: Kenneth E. Schwartz
-
Patent number: 6849713Abstract: The present invention provides novel compounds possessing one or more of the following activities: antibacterial, antifungal and antitumor activity. The compounds are of Formula (I): Pharmaceutical compositions containing these compounds, methods of making and methods for using these compounds are also provided.Type: GrantFiled: June 26, 2001Date of Patent: February 1, 2005Assignee: Genelabs Technologies, Inc.Inventors: Wentao Zhang, Sebastian Johannes Reinhard Liehr, Mark Douglas Velligan, Natalia B. Dyatkina, Janos Botyanszki, Dong-Fang Shi, Christopher Don Roberts, Alexander Khorlin, Peter Harold Nelson, Joseph Martin Muchowski
-
Patent number: 6838556Abstract: This invention provides nucleic acid sequences, vectors and host cells comprising regulatory regions associated with various promoters including a cyclin D1 promoter, a CD40L promoter, three HBV promoters (core, pre-S1 and HBV-X), a vancomycin-resistant enterococci (VRE) promoter, an androgen receptor promoter, a Her2 promoter, and ?-lactamase promoter. The invention further provides methods of regulating gene expression comprising the regulatory regions of such promoters.Type: GrantFiled: June 6, 2001Date of Patent: January 4, 2005Assignee: Genelabs Technologies, Inc.Inventors: Jungsuh P. Kim, Douglas B. Starr, Albert W. Tam, Megan E. Laurance, Emil F. Michelotti, Mark D. Velligan, Derek R. Latour, Rita L. Thomas, Ana Kongpachith, Liana T. Sheppard, Moon Young Kim, Thomas W. Bruice
-
Publication number: 20040147464Abstract: Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.Type: ApplicationFiled: September 30, 2003Publication date: July 29, 2004Applicant: Genelabs Technologies, Inc.Inventors: Christopher Don Roberts, Natalia B. Dyatkina
-
Publication number: 20030181435Abstract: This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.Type: ApplicationFiled: January 8, 2003Publication date: September 25, 2003Applicant: Genelabs Technologies, Inc.Inventors: Kenneth E. Schwartz, Marc J. Gurwith
-
Publication number: 20030170714Abstract: Substantially-isolated polynucleotides encoding human polypeptides having immunomodulatory activity; human homologs of yeast RAD50, Drosophila Septin-2 and rat Acyl-CoA Synthetase compositions and methods; method for detecting the presence of activated T-cells.Type: ApplicationFiled: March 19, 2003Publication date: September 11, 2003Applicant: Genelabs Technologies, Inc.Inventor: Gregory Dolganov
-
Patent number: 6613517Abstract: The invention provides a novel nucleic acid binding assay, which is useful for assessing the sequence-dependence of the binding of ligands to nucleic acid molecules, as well as for determining the affinity of the binding interaction. The invention also provides a selection method based on this nucleic acid binding assay. This selection method allows co-selection of ligands and the nucleic acid molecules that they bind. Additionally, the invention provides kits that can be used for carrying out the methods of the invention.Type: GrantFiled: January 16, 2001Date of Patent: September 2, 2003Assignee: Genelabs Technologies, Inc.Inventor: Emil F. Michelotti
-
Publication number: 20030158159Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).Type: ApplicationFiled: February 13, 2003Publication date: August 21, 2003Applicant: Genelabs Technologies, Inc.Inventor: Kenneth E. Schwartz
-
Patent number: 6605591Abstract: A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).Type: GrantFiled: November 10, 2000Date of Patent: August 12, 2003Assignee: Genelabs Technologies, Inc.Inventor: Kenneth E. Schwartz
-
Publication number: 20030143241Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: ApplicationFiled: June 6, 2002Publication date: July 31, 2003Applicant: GeneLabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Publication number: 20030124530Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: ApplicationFiled: November 13, 2001Publication date: July 3, 2003Applicant: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 6552010Abstract: This invention provides a method of treating systemic lupus erythematosus (SLE) with (DHEA) and a related pharmaceutical product.Type: GrantFiled: November 10, 2000Date of Patent: April 22, 2003Assignee: Genelabs Technologies, Inc.Inventors: Kenneth E. Schwartz, Marc J. Gurwith
-
Patent number: 6455492Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: GrantFiled: April 20, 1992Date of Patent: September 24, 2002Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Publication number: 20020107360Abstract: Antigens are provided which are derived from the enterically transmitted non-A/non-B viral hepatitis agent, known as hepatitis E virus (HEV). The HEV antigens and in particular, soluble species of the capsid protein encoded by the carboxy terminal region of HEV ORF2, are immunoreactive with sera from individuals infected with HEV. In one embodiment, these antigens may be produced by a baculovirus expression vector and form virus-like particles (VLPs). The antigens are useful as diagnostic reagents in diagnostic methods and kits for determining infection of an individual with HEV. The antigens are also useful in vaccine compositions effective in methods for preventing HEV infection.Type: ApplicationFiled: May 29, 2001Publication date: August 8, 2002Applicant: Genelabs Technologies, Inc.Inventors: Thomas R. Fuerst, C. Patrick McAtee, Patrice O. Yarbough, Yi-Fan Zhang
-
Patent number: 6420109Abstract: Methods for determining the relative binding affinities of various ligands to various nucleic acid sequences are described. In a direct binding assay, the effect of adding increasing amounts of a ligand on a signal generated by two “indicator” oligonucleotides is observed. Also described is a competitive binding assay, in which a competitor oligonucleotide is added to an indicator duplex having a ligand bound thereto. The assays allow the rapid and convenient determination of nucleic acid binding specificities and base pair determinants of specificity of particular ligands.Type: GrantFiled: September 11, 1998Date of Patent: July 16, 2002Assignee: Genelabs Technologies, Inc.Inventors: Gary P. Schroth, Thomas Wayne Bruice, Young J. Suh
-
Patent number: 6384208Abstract: The present invention defines a DNA: protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.Type: GrantFiled: July 15, 1999Date of Patent: May 7, 2002Assignee: Genelabs Technologies, Inc.Inventors: Cynthia A. Edwards, Charles R. Cantor, Beth M. Andrews, Lisa M. Turin, Kirk E. Fry
-
Patent number: 6379891Abstract: Viral proteins derived from an enterically transmitted non-A/non-B viral hepatitis agent (HEV) are disclosed. In one embodiment, the protein is immunologically reactive with antibodies present in individuals infected with the viral hepatitis agent. This protein is useful in a diagnostic method for detecting infection by the enterically transmitted agent. Specific epitopes have been identified that are reactive with sera of individual infected with different strains of HEV. Also disclosed are DNA probes derived from a cloned sequence of the viral agent. These probes are useful for identifying and sequencing the entire viral agent and for assaying the presence of the viral agent in an infected sample, by using probe-specific amplification of virus-derived DNA fragments.Type: GrantFiled: April 19, 2000Date of Patent: April 30, 2002Assignees: The United States of America as represented by the Department of Health and Human Services, Genelabs Technologies, Inc.,Inventors: Gregory R. Reyes, Patrice O. Yarbough, Daniel W. Bradley, Krzysztof Z. Krawczynski, Albert Tam, Kirk E. Fry